A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT ID: NCT06362369
Last Updated: 2025-09-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
126 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-08-23
Study Completion Date
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
NCT03668119
Pan Tumor
COMPLETED
PHASE2
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
NCT04761198
Solid Tumor, Adult
Advanced Solid Tumor
Metastatic Solid Tumor
COMPLETED
PHASE1/PHASE2
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968109
Neoplasms by Site
COMPLETED
PHASE1/PHASE2
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483
Renal Cell Carcinoma (RCC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Urothelial Carcinoma (UC)
+7 more
ACTIVE_NOT_RECRUITING
PHASE1
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
NCT04938232
Hodgkin Lymphoma
Relapsed Hodgkin's Disease, Adult
Refractory Hodgkin Lymphoma
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This Phase study is designed to evaluate the safety, tolerability, and preliminary efficacy of oral Alintegimod (Alintegimod) alone, and then in combination with ipilimumab for, followed by nivolumab monotherapy cycles. All patients will receive nivolumab after completion of treatment with Alintegimod plus ipilimumab combination therapy to continue nivolumab treatment until the end of study (12 months) unless progression or toxicity result in early termination.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Cancer
Advanced Solid Tumor
Melanoma
Metastasis
Pleural Mesothelioma
Renal Cell Carcinoma
MSI-High
Mismatch Repair Deficiency
Colorectal Cancer
Hepatocellular Carcinoma
Hepatocellular Cancer
Renal Cell Cancer
Kidney Cancer
Skin Cancer
Non Small Cell Lung Cancer
NSCLC
Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
ALK Genomic Tumor Aberrations
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Phase 1b - Open Label
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation - Open Label Phase 1b
Alintegimod dose escalation, 4 cohorts Alintegimod monotherapy 1 cycle Alintegimod + Ipilimumab - 4 cycles Nivolumab - 11 cycles
Group Type
EXPERIMENTAL
Alintegimod
Intervention Type
DRUG
Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
Ipilimumab
Intervention Type
DRUG
Ipilimumab (Yervoy) will be administered via IV
Nivolumab
Intervention Type
DRUG
Nivolumab (Opdivo) will be administered via IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alintegimod
Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
Intervention Type
DRUG
Ipilimumab
Ipilimumab (Yervoy) will be administered via IV
Intervention Type
DRUG
Nivolumab
Nivolumab (Opdivo) will be administered via IV
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
7HP349
Yervoy
Opdivo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adult patients (age 18 or older)
2. Patient has a histologically confirmed diagnosis of any of the following locally advanced or metastatic solid tumors: melanoma, pleural mesothelioma, renal cell carcinoma, MSI-high or mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, or tumor types for which the combination of ipilimumab and nivolumab has been FDA approved. Patients may have received treatment with anti PD-1/PD-L1.
3. ANC ≥ 1000/µL without use of G-CSF, Hgb ≥ 9 g/dL without required blood transfusion for at least 5 days prior to pretreatment baseline, and platelet count ≥ 75,000/µL without transfusions for at least 5 days prior to pretreatment baseline.
4. ECOG performance status of 0 or 1.
5. Has a life expectancy of \> 12 weeks.
6. Renal and hepatic function requirements:
* a. Renal function with either an eCrCL ≥ 60 mL/min (modified Cockcroft-Gault) or eGFR ≥ 60 mL/min/1.73 m2 (using MDRD or CKD-EPI or similar equations).
* b. Hepatic function with ALT/AST ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert Syndrome). If patients have hepatic metastases, then AST/ALT≤ 5 x ULN will be allowed.
2. Patient has a histologically confirmed diagnosis of any of the following locally advanced or metastatic solid tumors: melanoma, pleural mesothelioma, renal cell carcinoma, MSI-high or mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, or tumor types for which the combination of ipilimumab and nivolumab has been FDA approved. Patients may have received treatment with anti PD-1/PD-L1.
3. ANC ≥ 1000/µL without use of G-CSF, Hgb ≥ 9 g/dL without required blood transfusion for at least 5 days prior to pretreatment baseline, and platelet count ≥ 75,000/µL without transfusions for at least 5 days prior to pretreatment baseline.
4. ECOG performance status of 0 or 1.
5. Has a life expectancy of \> 12 weeks.
6. Renal and hepatic function requirements:
* a. Renal function with either an eCrCL ≥ 60 mL/min (modified Cockcroft-Gault) or eGFR ≥ 60 mL/min/1.73 m2 (using MDRD or CKD-EPI or similar equations).
* b. Hepatic function with ALT/AST ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert Syndrome). If patients have hepatic metastases, then AST/ALT≤ 5 x ULN will be allowed.
Exclusion Criteria
8. All Grade 3 AEs related to prior therapies have returned to Grade 1 or resolved to baseline (this includes with appropriate therapy in the case of thyroid dysfunction).
9. All patients must have measurable disease by applicable RECIST criteria.
10. Willing to allow blood samples to be used for research.
1. Patients must not have received prior anticancer therapy or radiation therapy within the 3 weeks and must not have undergone major surgery within 4 weeks prior to initiation of treatment on protocol. Palliative radiation therapy is allowed. For small molecules (MW \< 0.9 kDA), the washout period is 3 weeks or 5 half-lives, whatever comes first.
2. Active brain metastasis or leptomeningeal disease. Patients with treated brain metastasis must have stable disease, evidenced by MRI brain imaging for at least 4 weeks, and the patient must have been off steroids for at least 2 weeks prior to first dose of study drug.
3. Previous episodes of ≥ Grade 3 (G3) immune-related toxicity that includes G3 colitis, G3 pneumonitis, G3 skin rash, G3 increase in liver enzymes (with the exception of symptoms that in the opinion of the investigator will not compromise the patients' safety on the trial. Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) are allowed.
4. Persistent toxicity of NCI CTCAE version 5 Grade \> 1 severity that is related to prior therapy.
Note: Sensory neuropathy, hypothyroidism or alopecia of Grade ≤ 2 are acceptable. Other Grade 2 toxicities of prior treatments that are controlled with medication (e.g., diabetes or hypertension) are permitted.
5. Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome p450 3A (CYP3A) within 2 weeks before study intervention. Alintegimod may increase exposure to CYP3A4 substrates; consider a dose reduction of such substrates and monitor for signs of toxicities of co-administered sensitive CYP3A substrates (see listing of strong inhibitors and inducer drugs in FDA tables). An alternative is to replace such agents with drugs that are not CYP3A4 metabolized if at all feasible.
6. The patient has cardiac conditions as follows:
* a) myocarditis;
* b) uncontrolled hypertension (blood pressure \> 160/100) despite optimal therapy;
* c) uncontrolled angina; ventricular arrhythmias; congestive heart failure (New York Heart Association Class II or above);
* d) prior or current cardiomyopathy;
* e) uncontrolled atrial fibrillation with heart rate \> 100 beats per minute (bpm); unstable ischemic heart disease (myocardial infarction within 6 months prior to starting treatment or angina requiring use of nitrates more than once weekly);
* f) concomitant medication with drugs known to cause Torsades de Pointes;87
* g) QT interval correction for heart rate using Fridericia's formula (QTcF) ≥ 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram \[ECG\]) at screening.
7. Known history of a positive test for HIV, or positive test for hepatitis B (positive for HBsAg) or hepatitis C (HCV RNA).
8. Concurrent malignancies are permitted if they were previously treated, and all treatment of that malignancy was completed at least 2 years before enrollment and no evidence of disease exists, or with agreement from the Principal Investigator (PI), patients who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment are eligible to participate if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low, or with agreement from the PI, other malignancies may be permitted if the risk of the prior malignancy interfering with either safety or efficacy end points is very low. Adequately treated basal or squamous cell carcinoma or carcinoma in situ is allowed.
10. The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).
11. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of administration of Alintegimod with the following exceptions:
* a) Topical, intranasal, inhaled, ocular, intra-articular corticosteroids;
* b) Physiological doses of replacement corticosteroids (e.g., for adrenal insufficiency) are not to exceed 10 mg/day of prednisone or equivalent.
* c) Corticosteroid premedication for infusion and/or hypersensitivity reactions.
* d) Patients may be treated with a short (\<24h) pulse course of corticosteroids to mitigate infusion or hypersensitivity reactions to radiocontrast agents.
12. Receipt of live attenuated vaccine within 28 days of the first dose of Alintegimod.
13. Serious autoimmune disease at the discretion of the treating Investigator: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's Granulomatosis) are excluded from participation in this study
14. Active or history of pneumonitis (drug-induced), idiopathic pulmonary fibrosis, Interstitial Lung Disease (ILD), or lung disease that may interfere with assessment of pneumonitis. History of radiation pneumonitis in a previous radiation field is permitted.
15. Previous participation in a study of any investigational agent within 21 days of enrollment or within 5 half-lives of the study treatment, whichever is the least.
16. Use of mechanical ventilation or having a resting O2 saturation \< 90% (on room air) by pulse-oximetry, require renal dialysis, require vasopressors, and/or severe hepatic sinusoidal obstruction syndrome.
17. Proven or suspected ongoing systemic infection requiring IV antibiotics.
18. Women who are pregnant or lactating.
Note: Women of childbearing potential (WOCBP) must have a "negative" serum pregnancy test within 1 week prior to treatment. Non-childbearing potential is defined as 1 of the following:
* a) Postmenopausal with \> 1 year since last menses and:
* 1\. If ≥ 65 years old, follicle-stimulating hormone (FSH) \> 40 mIU/mL.
* 2\. If ≥ 65 years old and not on hormone replacement therapy (HRT), FSH \> 30 mIU/mL.
* 3\. If ≥ 65 years old and on HRT, the FSH requirement is not applicable. Postmenopausal females on HRT will be allowed if HRT has been stable for ≥ 6 months prior to dosing of study drug(s).
* b) Written medical documentation of being sterilized (e.g., hysterectomy, double oophorectomy, bilateral salpingectomy) with the procedure performed ≥ 6 months prior to dosing study drug(s).
Note: Tubal ligation is not considered a form of permanent sterilization.
19. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of adverse events or have compromised ability to provide written informed consent.
20. Patients who have had allogeneic tissue or solid organ transplantation. Prior T cell therapy is allowed
21. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg (NIH-ODS 2022; Section 5.9.2.1).
Note: Patients who switch from a high dose to a dose of ≤30 µg/day are eligible for study entry.
22. Any condition that is in the opinion of the investigator may compromise patient's participation in the trial.
23. Active peptic ulcer disease or gastritis, active diverticulitis, or other serious gastrointestinal disease associated with diarrhea within the past 2 years before the start of therapy or GI disease which affects oral drug absorption.
24. Patients with known soy allergy.
9. All patients must have measurable disease by applicable RECIST criteria.
10. Willing to allow blood samples to be used for research.
1. Patients must not have received prior anticancer therapy or radiation therapy within the 3 weeks and must not have undergone major surgery within 4 weeks prior to initiation of treatment on protocol. Palliative radiation therapy is allowed. For small molecules (MW \< 0.9 kDA), the washout period is 3 weeks or 5 half-lives, whatever comes first.
2. Active brain metastasis or leptomeningeal disease. Patients with treated brain metastasis must have stable disease, evidenced by MRI brain imaging for at least 4 weeks, and the patient must have been off steroids for at least 2 weeks prior to first dose of study drug.
3. Previous episodes of ≥ Grade 3 (G3) immune-related toxicity that includes G3 colitis, G3 pneumonitis, G3 skin rash, G3 increase in liver enzymes (with the exception of symptoms that in the opinion of the investigator will not compromise the patients' safety on the trial. Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) are allowed.
4. Persistent toxicity of NCI CTCAE version 5 Grade \> 1 severity that is related to prior therapy.
Note: Sensory neuropathy, hypothyroidism or alopecia of Grade ≤ 2 are acceptable. Other Grade 2 toxicities of prior treatments that are controlled with medication (e.g., diabetes or hypertension) are permitted.
5. Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome p450 3A (CYP3A) within 2 weeks before study intervention. Alintegimod may increase exposure to CYP3A4 substrates; consider a dose reduction of such substrates and monitor for signs of toxicities of co-administered sensitive CYP3A substrates (see listing of strong inhibitors and inducer drugs in FDA tables). An alternative is to replace such agents with drugs that are not CYP3A4 metabolized if at all feasible.
6. The patient has cardiac conditions as follows:
* a) myocarditis;
* b) uncontrolled hypertension (blood pressure \> 160/100) despite optimal therapy;
* c) uncontrolled angina; ventricular arrhythmias; congestive heart failure (New York Heart Association Class II or above);
* d) prior or current cardiomyopathy;
* e) uncontrolled atrial fibrillation with heart rate \> 100 beats per minute (bpm); unstable ischemic heart disease (myocardial infarction within 6 months prior to starting treatment or angina requiring use of nitrates more than once weekly);
* f) concomitant medication with drugs known to cause Torsades de Pointes;87
* g) QT interval correction for heart rate using Fridericia's formula (QTcF) ≥ 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram \[ECG\]) at screening.
7. Known history of a positive test for HIV, or positive test for hepatitis B (positive for HBsAg) or hepatitis C (HCV RNA).
8. Concurrent malignancies are permitted if they were previously treated, and all treatment of that malignancy was completed at least 2 years before enrollment and no evidence of disease exists, or with agreement from the Principal Investigator (PI), patients who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment are eligible to participate if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low, or with agreement from the PI, other malignancies may be permitted if the risk of the prior malignancy interfering with either safety or efficacy end points is very low. Adequately treated basal or squamous cell carcinoma or carcinoma in situ is allowed.
10. The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).
11. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of administration of Alintegimod with the following exceptions:
* a) Topical, intranasal, inhaled, ocular, intra-articular corticosteroids;
* b) Physiological doses of replacement corticosteroids (e.g., for adrenal insufficiency) are not to exceed 10 mg/day of prednisone or equivalent.
* c) Corticosteroid premedication for infusion and/or hypersensitivity reactions.
* d) Patients may be treated with a short (\<24h) pulse course of corticosteroids to mitigate infusion or hypersensitivity reactions to radiocontrast agents.
12. Receipt of live attenuated vaccine within 28 days of the first dose of Alintegimod.
13. Serious autoimmune disease at the discretion of the treating Investigator: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's Granulomatosis) are excluded from participation in this study
14. Active or history of pneumonitis (drug-induced), idiopathic pulmonary fibrosis, Interstitial Lung Disease (ILD), or lung disease that may interfere with assessment of pneumonitis. History of radiation pneumonitis in a previous radiation field is permitted.
15. Previous participation in a study of any investigational agent within 21 days of enrollment or within 5 half-lives of the study treatment, whichever is the least.
16. Use of mechanical ventilation or having a resting O2 saturation \< 90% (on room air) by pulse-oximetry, require renal dialysis, require vasopressors, and/or severe hepatic sinusoidal obstruction syndrome.
17. Proven or suspected ongoing systemic infection requiring IV antibiotics.
18. Women who are pregnant or lactating.
Note: Women of childbearing potential (WOCBP) must have a "negative" serum pregnancy test within 1 week prior to treatment. Non-childbearing potential is defined as 1 of the following:
* a) Postmenopausal with \> 1 year since last menses and:
* 1\. If ≥ 65 years old, follicle-stimulating hormone (FSH) \> 40 mIU/mL.
* 2\. If ≥ 65 years old and not on hormone replacement therapy (HRT), FSH \> 30 mIU/mL.
* 3\. If ≥ 65 years old and on HRT, the FSH requirement is not applicable. Postmenopausal females on HRT will be allowed if HRT has been stable for ≥ 6 months prior to dosing of study drug(s).
* b) Written medical documentation of being sterilized (e.g., hysterectomy, double oophorectomy, bilateral salpingectomy) with the procedure performed ≥ 6 months prior to dosing study drug(s).
Note: Tubal ligation is not considered a form of permanent sterilization.
19. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of adverse events or have compromised ability to provide written informed consent.
20. Patients who have had allogeneic tissue or solid organ transplantation. Prior T cell therapy is allowed
21. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg (NIH-ODS 2022; Section 5.9.2.1).
Note: Patients who switch from a high dose to a dose of ≤30 µg/day are eligible for study entry.
22. Any condition that is in the opinion of the investigator may compromise patient's participation in the trial.
23. Active peptic ulcer disease or gastritis, active diverticulitis, or other serious gastrointestinal disease associated with diarrhea within the past 2 years before the start of therapy or GI disease which affects oral drug absorption.
24. Patients with known soy allergy.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
7 Hills Pharma, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lionel Lewis, MA, MB.Bch, MD
Role: STUDY_CHAIR
7 Hills Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Florida Cancer Specialists
Lake Mary, Florida, United States
Site Status
RECRUITING
Dartmouth Hitchcock
Lebanon, New Hampshire, United States
Site Status
RECRUITING
Brown University Health Cancer Institute
Providence, Rhode Island, United States
Site Status
RECRUITING
MD Anderson Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
603.650.6345
Study Coordinator
Role: primary
713.792.4259
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7HP-111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890
RECRUITING
PHASE2
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
NCT00363090
UNKNOWN
PHASE1/PHASE2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
NCT03521830
RECRUITING
PHASE2
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
NCT02996110
COMPLETED
PHASE2
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018
ACTIVE_NOT_RECRUITING
PHASE2
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT06708949
RECRUITING
PHASE2
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
NCT01822509
COMPLETED
PHASE1
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976
ACTIVE_NOT_RECRUITING
PHASE1
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496
COMPLETED
PHASE1
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
NCT03447314
COMPLETED
PHASE1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978
ACTIVE_NOT_RECRUITING
PHASE1
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
NCT00089271
COMPLETED
PHASE1
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00354185
TERMINATED
PHASE1
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068
COMPLETED
PHASE1
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
RECRUITING
PHASE2
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996
RECRUITING
PHASE3
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT02500407
COMPLETED
PHASE1/PHASE2
Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.
NCT01019863
UNKNOWN
PHASE2
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
NCT04668690
ACTIVE_NOT_RECRUITING
PHASE3
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00069966
UNKNOWN
PHASE2
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
NCT03677141
COMPLETED
PHASE1/PHASE2
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
NCT02603445
COMPLETED
PHASE1
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
NCT04923048
UNKNOWN
PHASE1/PHASE2